Related Experiment Video
Updated: May 7, 2026

A Primary Neuron Culture System for the Study of Herpes Simplex Virus Latency and Reactivation
Published on: April 2, 2012
Anti-HSV-1 agents: an update
Wenwen Lv1, Lei Zhou1, Jia Wu2
1College of Pharmaceutics, Kunming Medical University, Kunming, China.
Abstract:
Herpes simplex virus type I (HSV-1) is a member of the α-herpesvirus subfamily and is capable of causing herpes simplex keratitis, herpes labialis, and herpes simplex encephalitis. HSV-1 is well known for its lytic infections at the primary sites and for establishing latency in the sensory neuronal ganglia, with occasional recurrent infections. To date, there are no approved commercially available vaccines, and anti-HSV-1 drugs such as specific or non-specific nucleotide (nucleoside) analogs and helicase-primase inhibitors have become the main clinical agents for the treatment of HSV-1 infections despite challenges from resistance. Therefore, development of new anti-HSV-1 compounds or therapies is key to addressing the issue of resistance. The present review provides an update on the progress made over approximately 60 years regarding anti-HSV-1 agents while also highlighting future perspectives for controlling HSV-1 infections.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Subviral Agents
Cytomegalovirus Disease
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction

